Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001931
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2007-07-31
Brief Title:
Treatment of Parkinsons Disease With a Transdermal Skin Patch
Sponsor:
National Institute of Neurological Disorders and Stroke NINDS
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Transdermal Application of Dopamine Agonist N-0923 in Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2000-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with Parkinsons disease are missing the chemical neurotransmitter dopamine This occurs as a result of destructive changes in an area of the brain responsible for making dopamine the basal ganglia Muscle tremors rigidity of movement shuffling footsteps droopy posture and a mask-like expression on the face characterize Parkinsons disease
This study is designed to determine the effects of a new drug N-9023 The drug acts like dopamine and can be given through a skin patch transdermal for treatment of parkinsonian symptoms
The goals of this study are to find out whether N-9023 is useful in treating the signs and symptoms of Parkinsons disease and to determine the best dose of N-9023 that is safe and effective
This study is designed to determine the effects of a new drug N-9023 The drug acts like dopamine and can be given through a skin patch transdermal for treatment of parkinsonian symptoms
The goals of this study are to find out whether N-9023 is useful in treating the signs and symptoms of Parkinsons disease and to determine the best dose of N-9023 that is safe and effective
Detailed Description:
The acute safety and antiparkinsonian efficacy of transdermally delivered N-0923 will be evaluated in patients with Parkinsons disease This dopamine receptor agonist will be administered transdermally under double-blind conditions in a rising dose paradigm Antiparkinsonian activity will be quantified by means of standard rating scales Possible adverse events will be assessed by appropriate clinical and laboratory tests
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 99-N-0104 | None | None | None |